Merck & Co., Inc. Sees Institutional Investment Surge

Oversea Chinese Banking Corp Ltd has taken a $969,000 position in Merck & Co., Inc. (NYSE:MRK) by buying 7,538 shares of the company's stock in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). This is not an isolated instance, as several other institutional investors have also added to or reduced their stakes in MRK. For example, Kingdom Financial Group LLC bought a new position in shares of Merck & Co., Inc. in the fourth quarter valued at about $25,000.

The stock has a market cap of $378 billion and a debt-to-equity ratio of 1.22. Merck & Co., Inc. has reported positive results for its melanoma treatment, intismeran autogene, an individualized neoantigen therapy used with KEYTRUDA in resected melanoma. This could create a new growth opportunity and help extend KEYTRUDA's commercial runway.

Several analysts have issued reports on MRK shares, upgrading their price targets and ratings. Wolfe Research raised its target from $155 to $180 with an outperform rating, while Argus increased its target from $145 to $170 and upgraded the stock to buy.